Amphastar Pharmaceuticals Inc [AMPH] stock is trading at $26.6, up 0.38%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AMPH shares have gain 5.26% over the last week, with a monthly amount glided 4.85%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amphastar Pharmaceuticals Inc [NASDAQ: AMPH] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Equal Weight rating and assigned the stock a price target of $30. Previously, Needham upgraded its rating to Buy on August 12, 2025, and kept the price target unchanged to $36. On May 12, 2025, downgrade downgraded it’s rating to Neutral but maintained its price target of $30 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $36 on February 04, 2025. Wells Fargo initiated its recommendation with a Equal Weight and recommended $55 as its price target on November 22, 2024. JP Morgan started tracking with a Overweight rating for this stock on March 05, 2024, and assigned it a price target of $60. In a note dated November 17, 2023, BofA Securities initiated an Neutral rating and provided a target price of $63 on this stock.
Amphastar Pharmaceuticals Inc [AMPH] stock has fluctuated between $20.39 and $40.74 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Amphastar Pharmaceuticals Inc [NASDAQ: AMPH] shares were valued at $26.6 at the most recent close of the market. An investor can expect a potential return of 12.78% based on the average AMPH price forecast.
Analyzing the AMPH fundamentals
Amphastar Pharmaceuticals Inc [NASDAQ:AMPH] reported sales of 723.30M for the trailing twelve months, which represents a growth of 0.33%. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.15 and Total Capital is 0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.85.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.35 points at the first support level, and at 26.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.82, and for the 2nd resistance point, it is at 27.05.
Ratios To Look Out For
For context, Amphastar Pharmaceuticals Inc’s Current Ratio is 3.12. Also, the Quick Ratio is 2.21, while the Cash Ratio stands at 1.05. Considering the valuation of this stock, the price to sales ratio is 1.69, the price to book ratio is 1.59 and price to earnings (TTM) ratio is 11.79.
Transactions by insiders
Recent insider trading involved Zhou Rong, SENIOR EVP, PRODUCTION CENTER, that happened on Dec 17 ’25 when 9787.0 shares were sold. Director, Petersen Floyd F. completed a deal on Dec 12 ’25 to sell 2426.0 shares. Meanwhile, Director Petersen Floyd F. sold 1737.0 shares on Dec 11 ’25.
